... the apolipoprotein E (APOE) ε4 allele are at greater risk of developing Alzheimer disease (AD) than men, and the sex-dependent association of mild cognitive ... MCI and AD AbstractText: Twenty-seven independent research studies in the Global Alzheimer's Association Interactive Network with data on nearly 58 000 participants AbstractText: Non ...
Neurological and Central Nervous System Diseases (1), Neuroscience (1) Alzheimer Disease (3), Mild Cognitive Impairment (1), more mentions
Abstract: Purpose To assess the relative risk of Alzheimer's disease (AD) among patients with prostate cancer who received androgen deprivation therapy (ADT), after adjustment for other cancer therapies. Methods Data from demographics, survival, diagnoses codes, procedure codes, and other information about beneficiaries age 67 years or older in the Medicare claims database was assessed to determine the unadjusted and adjusted ...
AbstractText: This observational multimodality brain imaging study investigates emergence of endophenotypes of late-onset Alzheimer disease (AD) risk during endocrine transition states in a cohort of clinically and cognitively normal women and age-matched men AbstractText: Forty-two 40- to 60-year-old cognitively normal women (15 asymptomatic perimenopausal by ...
... evaluate the association between zolpidem use and the incidence of Alzheimer's disease AbstractText: Zolpidem users with a high cumulative dose (>180 ... first year after initiation had a significantly greater risk of Alzheimer's disease than non-zolpidem users (HR = 2.97, 95% CI = 1.61 ... dose of zolpidem was associated with an increased risk of Alzheimer's disease among older people living in Taiwan.
... or tau and rates of hippocampal atrophy in patients with Alzheimer's disease... analysed post-mortem brain tissue of all individuals with an Alzheimer's disease spectrum pathological diagnosis who had antemortem head MRI scans ... 2012, and who had been recruited into the Mayo Clinic Alzheimer's Disease Research Center, Mayo Clinic Alzheimer's Disease Patient Registry, or the Mayo Clinic Study of Aging ...
Neuroscience (12) Alzheimer Disease (12), Atrophy (11), more mentions
... homeostasis or tissue changes induce several dynamic microglial processes, including changes of cellular morphology, surface phenotype, secretory mediators, and proliferative responses (referred to as an "activated state. Activated microglia represent a common pathological feature of several neurodegenerative diseases, including Alzheimer's disease (AD. Cumulative evidence suggests that microglial inflammatory activity in AD is increased while microglial-mediated clearance mechanisms are compromised.
Neuroscience (2) Alzheimer Disease (2), Neurodegenerative Diseases (1), more mentions
To cross-sectionally study subjective memory complaints (SMC) in autosomal dominant Alzheimer disease (ADAD).We examined self-reported and study partner-based SMC in 52 young, cognitively unimpaired individuals from a Colombian kindred with early-onset ADAD. Twenty-six carried the PSEN-1 E280A mutation, averaging 7 years of age younger than the kindred's expected clinical onset.
Alzheimer's disease (AD; n = 164) was identified with 70% sensitivity and specificity, which after the incorporation of apolipoprotein ε4 genotype (APOE ε4) information, increased to 86% when individuals carried one or ... Our method allows for both rapid and robust diagnosis of neurodegeneration and segregation between different dementias Keyword: Alzheimer’s disease.
Neuroscience (6), Neurological and Central Nervous System Diseases (1) Alzheimer Disease (3), Dementia (3), Neurodegenerative Diseases (3), more mentions
Abstract: Alzheimer's disease (AD) causes alterations of brain network structure and function. The latter consists of connectivity changes between oscillatory processes at different frequency channels. We proposed a multi-layer network approach to analyze multiple-frequency brain networks inferred from magnetoencephalographic recordings during resting-states in AD subjects and age-matched controls.
... it is still unclear whether taking antidepressants before or after a diagnosis of dementia influences survival AbstractText: Retrospective AbstractText: A cohort with a diagnosis of Alzheimer disease (AD) from a large mental health and dementia care database in South London, linked to hospitalization and mortality data AbstractText: Mild dementia (Mini-Mental ...
Neuroscience (11) Dementia (10), Alzheimer Disease (2), more mentions
AbstractText: We have previously reported high dopamine D2/3 receptor occupancies at low amisulpride concentrations in older people with Alzheimer's disease (AD), during off-label treatment of AD-related psychosis. This post hoc analysis explored pharmacokinetic (concentration) and pharmacodynamic (prolactin, D2/3 occupancy) contributions to symptom reduction and extrapyramidal side effects (EPS) to inform AD-specific dose adjustments AbstractText: Population ...
Neuroscience (2) Psychotic Disorders (3), Alzheimer Disease (2), more mentions
Neuroimaging and other biomarker assays suggest that the pathological processes of Alzheimer's disease (AD) initiate years prior to clinical dementia onset. However some 30%-50% of older individuals that harbor AD pathology do not become symptomatic in their lifetime. It is hypothesized that such individuals exhibit cognitive resilience that protects against AD dementia.
... triggering receptor expressed on myeloid cells 2 (TREM2) support an essential function of microglia and innate immunity in the pathogenesis of Alzheimer's disease (AD) and other neurodegenerative disorders... cellular effects of TREM2 variants, namely reduced versus enhanced shedding, result in similar phenotypic outcomes by reducing cell surface TREM2 Keyword: Alzheimer's disease.
Neuroscience (2) Alzheimer Disease (3), Neurodegenerative Diseases (1), more mentions
... cerebral amyloid angiopathy is particularly important when planning to start or restart anticoagulation after an intracerebral hemorrhage. Given the lack of randomized trial data to guide management strategies, we discuss a heart-brain team approach that includes clinician-patient shared decision making for the use of pharmacologic and nonpharmacologic approaches to diminish stroke risk Keyword: Alzheimer’s dementia. Keyword: atrial fibrillation.